Nuvectis Pharma (NVCT) Profit After Tax (2021 - 2026)

Nuvectis Pharma has reported Profit After Tax for 6 years, with the latest figure at -$6.0 million in Q1 2026.

• Quarterly Profit After Tax fell 13.47% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.2 million (down 34.72% YoY) and the FY2025 annual result came in at -$26.4 million, down 39.17% from the prior year.
• Profit After Tax improved to -$6.0 million in Q1 2026 per NVCT's latest filing, from -$7.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$2.9 million in Q1 2022 and troughed at -$7.5 million in Q3 2025.
• A 5-year average of -$5.5 million and a median of -$5.9 million in 2022 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 39.9% in 2022, down 196.15% in 2022.
• Over 5 years, Profit After Tax stood at -$6.7 million in 2022, then climbed by 1.11% to -$6.6 million in 2023, then rose by 5.65% to -$6.2 million in 2024, then dropped by 17.06% to -$7.3 million in 2025, then gained by 17.28% to -$6.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$6.0 million, -$7.3 million, and -$7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.